
Witness Name: Glenn Wilkinson Statement No.: WITN2050001 Exhibits: WITN2050002 – WITN2050114 Dated: 14 August 2020

INFECTED BLOOD INQUIRY

EXHIBIT WITN2050022



Introduction

This report contains general details of the Research and Development programme which has taken place during the year January to December 1984 and follows on from the previous report.

The year has maintained the continuous process of selection and reselection of projects to meet the ever-changing demands made on the organisation through requirements for new products or modifications to existing products to improve safety and efficacy.

The outstanding example this year has been the concurrence of requirements for improved product safety due to the presence of viruses causing non-A non-B hepatitis and the Acquired Immune Deficiency Syndrome. The widely-based group of projects aimed at purifying factor VIII to enable it to be satisfactorily heat-treated to inactivate non-A non-B hepatitis viruses has provided the means to inactivate HTLV III. The new factor VIII product, VIII-Y, materialised during the summer 1984 and is now successfully in clinical trial. Patent applications on the process will be submitted by the end of March 1985. VIII-Y has increased purity by more than one order of magnitude and tolerates more heat than is being applied to any other commercial factor VIII at present on the market, i.e. 80°C for 72 hours: yields are satisfactory and will not threaten existing plans for plasma

The VIII-Y story underlines the importance of having a widely-based active research programme from which major advances can be made with all possible speed as demand arises.

One outstanding problem now remains in repeating the success with factor VIII in the more complex area of factor IX, and a major allocation of resources to meet this end is now established. This year BPL requires factor IX which is non-thrombogenic and free from transmission of HTLV III and other viruses causing hepatitis. The current requirement is for 15M international units per annum, which at current market rates would cost the NHS between £2M and £3M per annum.

The general report follows, then there are papers; which show the estimates of expenditure for 1985/86 and the way in which it is distributed. There is finally the project index to the main report of projects. The main report of projects is confidential and is available to the Authority and its members on request. In this way its circulation will be reduced and detailed discussion on projects can be had with the Director and the Head of Research and Development.



Research and Development Programme



The continuous review of project status throughout the year has resulted six projects being merged into three revised projects; fifteen new projects have been started in response to internal and external demands; six projects have been completed and a further ten projects have been held, or shelved, pending further information or changes in emphasis. Details of all projects are given in the annual R & D project report.

The major thrust of this year's programme has been in developing methods for virus inactivation, especially non-A, non-B Hepatitis viruses (NANBH). Fortuitiously the recognition that the clinical condition AIDS is initiated by infection with the retrovirus HTLV III, and the implications this had for blood products, was covered within this research remit. It is well established that almost all previously untreated patients with no prior immunity to hepatitis viruses acquire NANBH after their first one or two infusions of either factor VIII or factor IX. The infection is often apparently trivial or sub-clinical but it is feared that more serious chronic liver damage may develop in later life. Heating coagulation factor concentrates in either the lyophilised state or in protective solutions is thought to be an effective action against NANBH viruses, HTLV III and other retroviruses. Routine batches of intermediate potency factor VIII have survived heating with acceptable factor VIII yields but some loss of solubility, this parameter has been resolved by the addition of sucrose to the factor VIII concentrate. The results from three batches which have been infused into factor VIII-deficient patients are encouraging. Each subject has been followed up for one year, six months and two months respectively; recovery, half-life and clinical effect have been normal without any adverse effects. No clinical attacks of hepatitis have been recorded and to date there has been no serological evidence of hepatitis A or B, CMV or HTLV III infection, and no evidence of NANBH from liver function tests. Similar dryheat pasteurisation regimes have been successfully applied to routine factor IX concentrates. Clinical infusions of heated factor IX are scheduled for late 1985 on the satisfactory outcome of the current dog infusion studies with respect to potential thrombogenicity. Contingency programmes are in hand for both factor VIII and factor IX should process modifications be required, these include treating the concentrates with detergents designed to disrupt retroviruses and methods of heating in solution. The clinical trial of pasteurised antithrombin III has been extended with consistent clinical efficacy and no evidence of hepatitis transmission. The first pasteurised therapeutic concentrate of factor XIII, developed at PFL, has beer successfully infused into a patient.

Undoubtedly one of the most significant advances in the past year has been the development of the new 'high purity' factor VIII concentrate. The method selectively precipitates 90% of the fibrinogen and 70% of the fibronectin present in a cryoprecipitate extract, while factor VIII remain virtually guantitatively in solution. Precipitation of the factor VIII yield a product with an 8-fold increase in specific activity when compared with th intermediate potency concentrate. Furthermore, the product can be subjecte to very severe heating, 70 or 800C for 72 hours without significant loss o factor VIII activity and very little loss of solubility. This process ha been rapidly transferred through pilot scale studies to successful 900k production runs. Product characteristics have remained consistent and it i expected that the new 'high purity' concentrate (8Y) will become the nationa product during 1985. The first batches for clinical trial were released a the end of February with a protocol designed to assess safety and efficac together with monitoring of possible transmission of HTLV III and vira hepatitis. Further processing of 8Y on chromatographic adsorbents results : a 5-10 fold increase in specific activity. The adsorbent has a high capacit for factor VIII and with recoveries in the 80-90% region offers a clea potential application for large-scale processing.

Considerable effort has been centred on the teparation and concentration i vitamin K-dependent proteins. This reflects a BpL production requirement or a method of preparing factor IX concentrate which does not involve dilution of cryosupernatant, and recognises the planned increase in production dilution of cryosupernatant. The single step preparation of factors IX, II in the new manufacturing unit. The single step preparation of factors IX, II and X from undiluted cryosupernatant has been achieved using DEAF-Sepharose at the 50kg pilot plant scale. A diluted factor VII concentrate is recovered from the same chromatographic process. The process is being refined, scaledup and its effect on other processes assessed while awaiting results from the on-going thrombogenicity trials in dogs.

Plasma quality and its effect on plasma proteins, particularly factor VIII, has been investigated. Problems associated with the operation of filtration pheresis machines have prevented a detailed assessment of filtered plasma. Preliminary results indicate a lower level of B-thromboglobulin and fibrinopeptide A than in centrifuged plasma suggesting that platelet disruption and thrombin activation are reduced during filtration pheresis. Two new machines have been installed at the Leeds and Sheffield transfusion centres and collection of samples for detailed analysis and pilot-scale factor VIII production has started. The effect of anticoagulant volume and concentration on plasma quality has been investigated in collaboration with Cambridge RTC. At low volumes of anticoagulant there was no evidence of poor mixing, factor VIII activity and total protein were not detectably different, and there was no apparent increase in protein degradation. The level of 5thromboglobulin was observed to increase with decreasing anticoagulant volumes suggesting greater platelet lysis; this effect, together with an increase in fibrinopeptide A, was more apparent in sodium citrate plasma than CPD plasma. Cryoprecipitate produced from these experimental plasmas showed no difference in factor VIII activity or fibrinogen concentration; fibronectin levels appear to be a function of the anticoagulant volume. substantiated, would reduce the volume of 5,000 donations by 240 litres, thereby allowing an increase in the plasma content of each production batch with a concommitant decrease in the amount of water, buffer and ethanol used in the manufacturing process.

Clinicians continue to express interest in the availability of fibronectin and α_1 -antitrypsin. The introduction of a new process for the preparation of factor VIII (8Y) necessitates a re-evaluation of the method: established for fibronectin preparation. Notwithstanding, the principle barrier to the release of fibronectin for clinical assessment remains the lac of an acceptable reliable assay for in vivo function. This deficienc severely limits our capacity to investigate the pasteurisation procedure required before product release. Assay development and assessment ar proceeding; a candidate for the measurement of relevant biological activity developed at Birmingham University, has been incorporated into a wor programme directed ultimately to the clinical use of fibronectin concentrate following thermal injury. The British Thoracic Association continue t maintain a keen interest in the availability of al-antitrypsin for replacemen therapy in emphysema. More recently we have been approached for a supply (al-antitrypsin for use in heart/lung transplant patients. The preparation ('pure' al-antitrypsin has been achieved using Cohn fraction IV as a source material, however, for a variety of reasons the process cannot be transferrent to either pilot or full-scale production. Recognising the limitations impos by the use of fraction IV an alternative source material has been sought wi the initial objective of deriving an al-antitrypsin enriched concentra without detriment to the existing manufacturing process.

Following a commercial approach we have investigated the possibility preparing lys-plasminogen for use as an acylated complex in thromboly: therapy. Source materials have been defined and the appropriate asse established. The affinity adsorbent lysine-Sepharose has been prepared at E and elution conditions selected to yield glu-plasminogen at greater than 90% purity. Conversion to lys-plasminogen has been achieved by plasmin digestion and interim analysis suggest that the product will meet specifications. The lirst test sample (750mg) is now undergoing assessment.

The production of reagent grade albumin from waste Cohn fraction IV has been successfully scale-up to a level which can accommodate all the available fraction IV from production. The in-house preparation of the 40L blue-Sepharose column provides a system yielding 1.4kg albumin/10h cycle. The full potential of the automated system has been achieved through the introduction of a fraction IV clarification procedure based on graded sand bed filtration. Down-stream processing has been improved by modifications to existing diafiltration and ultrafiltration systems; sterile filtration and dispensing are now routinely employed. There has been a positive reaction to the use of the basic product in automated serology and in some instances this reaction The level of false positives has been extended to manual serology. experienced in manual serology with earlier batches has been reduced and results with a whole range of blood group antibodies have been more than equivalent to the results obtained using two commercial products. Various albumin treatments have been examined with a view to improving the performance of the product in manual serology. Gluteraldehyde cross-linking to increase the level of polymeric albumin has resulted in an improved reagent according to the recent trial undertaken by the ISBT/ICSH working party. In this comparative study against commercial products the BPL reagent gained top ranking in two of the three tests. However, two trial participants experienced false positive agglutinations with the displacement technique. A quality control programme involving 'in-house' characterisation and serological assessment by the Manchester RTC has been introduced to monitor reagent consistency. The occasional sub-standard preparation prevents the launch of a reagent for manual serology, however, the basic product for automated serology will be launched, after extensive field trials, later this vear.

Apart from albumin there are other reagent grade proteins derived from waste fractions of the manufacturing process, which appear to have marke potential. Preparations of transferrin and fibronectin have been assessed a tissue culture supplements with positive user reaction, however, the use o Cohn fraction IV as a direct replacement of foetal calf serum has not bee successful and further work is required to advance this product. There is a increasing demand for plasminogen in the assay of tissue plasminoge activators and a product, prepared from the waste fraction B+1, is currentl under assessment at CAMR, Porton. Other proteins requested as reagent-grad products include fibrinogen, thrombin, immunoglobulins and modified albumin The requirement for these products, excluding serological albumin, is largel unknown; a market survery will be initiated early this year to evaluate the: potential prior to deriving a costing programme.



WITN2050022 0005

4

per sondel

Two new scientific appointments were made at the beginning of the year; In Neal was employed to investigate the chromatographic fractionation of factor VIII and was assigned responsibility for reagent grade products. The continuity of the plasma filterpheresis programmes was as a project scientist to replace a maintained by appointing the science of the science of

Uctober and the department also lost the services of during the course of the year. The position of senior scientist has been filled by who comes to us with experience of both academic and industrial environments. Five new technicians have been appointed at BPL, and two replacement technicians have been taken on at PFL.

been promoted to a trainee management position at PFL, whilst and have been promoted to Senior Project Leader and Chief

Technician respectively.

Building

The conversion of Building 9 to give three new laboratories was completed in late summer. The area was commissioned in September and is operating at 40% occupancy. Further staffing is, in part, dependent upon the completion of an animal house facility for the department. Additional space has been released for laboratory work by acquiring a Portacabin to serve as office space for the Head of Department and the Department Secretary; was appointed to the latter position in October.

The scheduling of the new manufacturing unit to come on stream during early 1986 has considerable implications for the R & D department especially in relation to the life time of the pilot production facility (coagulation factors) at PFL. A facility appraisal report commissioned last year examined the options available for integrating the Oxford unit onto the Elstree site. The consultants after considering the feasibility and associated costs of reusing the existing production facility recommended the alternative approach of term stop gap plan which recognised the problems of accommodating the functions of the Department efficiently and acknowledged the necessary expansion of the Department's activities. It must be stressed that currently the Department, is unable to offer the necessary technical and scientific support essential to the production units and that this situation is likely to continue throughout the commissioning and early years of the new manufacturing unit.





3

BPL/PFL RESEARCH AND DEVELOPMENT

ESTIMATED EXPENDITURE 1985/86

All estimates, derived from the individual project reports, are for the year starting January 1985.

BPL Quality Control Department	12 100 (a)
BPL Production Units	301 200 (b)
BPL Research & Development Department	566 842 (c)
Plasma Fractionation Laboratory	<u>94 400</u> (ð)
	974 542

Notes :

- (a) Costs met from the Quality Control Department Budget.
- (b) Costs attributed to R & D projects are accommodated within the Production Department Budget; they include the purchase of developmental equipment for future use in routine production together with the estimated cost of the chimpanzee study on the new intravenous immunoglobulin preparation for freedom from transmission of non A, non B Hepatitis.

Tear-down machine development (CF/04)	70 000
Baemonetics plasma pack opening machine (CF/06)	50 000
Beat-treatment ovens (CF/07)	35 000
Chimpanzee study (IgG/01)	100 000
sub-total	255 000
Project expenditure (see R & D project report)	46 200
Tot	301,200

- (c) A breakdown of the Research & Development Department budget is given (the page (iii).
- (d) PFL estimates have been adjusted for GMP requirements and proportion according to the efforts of Research & Development, Fractionation as Quality Control in each project, taking into account the expensincurred in the Administration and Technical Support Groups.

BPL/PPL RESEARCE AND DEVI DISTRIBUTION OF BUDGET £295,312 PROCESS (a) Improvement of existing process ----- £87,850 8/01; 8/02; ALB/02; EF/02; EF/03; EF/05; CF/01; CF/02; CF/03; CF/04; CF/05; (b) New process development ----- £207,462 8/02; 8/05; 8/06; 8/07; 8/11; FT/01; 9/02; IgG/08; 19G/09; CF/06; CF/07; (a) Improvement of existing products ----- £71,400 8/03; 8/04; 8/10; 9/01; 9/03; FG/01; FN/04; 13/01; AT3/01; (b) Investigations on potential products (i) Clinical ----- £152,000 FN/01; ALB/05; AT/01; AT/23; IgG/01; IgG/02; IgG/03; PMG/01; (ii) Reagent ----- £64,850 PN/02; ALB/01; ALB/34; HEP/02; SMC/01; TCS/01; TF/01; Clq/01; PMG/02; RESEARCE £143,050 (a) Analytical developments ----- £56,250 FG/02; FG/04; FG/05; FN/06; FN/35; 19G/05; 1gG/06; IgG/07; LAL/01; LAL/02; LAL/03; HPLC/01; BPLC/02; BM/01; (b) Basic ----- £86,800 3GA/02; 3GA/03; MM/01; PP/01; ADC/01; MAB/01; CHR/01; COM/01; Sub total £726,61 Research & Development Department Expenses Administration overheads £106,598 £ 37,332 Equipment £104,000 External Research contracts £247,9 £247,930 £974,5 Total



_∖ ₽

÷,

\$



BPL RESEARCE AND DEVELOPMENT DEPARTMENT

1985/86 BUDGET

Forecast Expenditure :

Projects (see R & D project report) Equipment	318 912 37 332 356 244	356 244
Department administration/New staff Staff expenses V.A.T.	76 478 11 810 <u>18 310</u> <u>106 598</u>	106 598
External research	104 000	104 000

. A

Total submission 566 842

PROPERT INDEX

(New projects are denoted by an la

Topic : Coagulation Pactor VIII

Project Code

Estimated Budget : £105,562

- 8/01 Simultaneous removal of alhydrogel adsorbent and cold precipitate 8/02 Improved recovery with heparin as primary anticoagulant
- 8/02 Improved recovery with negatin as primary anticodeg 8/03 Inactivation of hepatitis viruses in concentrate
- B/03 Inactivation of nepatitis viruses in concentrate
 B/04 Precipitation behaviour and discrimination from fibrinogen
- 8/05 Molecular exclusion chromatography
- 8/06 Icn-exchange and hydrophobic interaction chromatography
- 8/07 Susceptibility to proteolytic activation
- * 8/10 Chromatography on anion-exchange media
- * 8/11 Anticoagulant volume : effect on factor VIII and plasma quality
- PT/01 Filterpheresis trials

Topic : Vitamin K dependent coagulation factors

Project Code

Estimated Budget : £55,000

- 9/01 Inactivation of hepatitis viruses in concentrates of factor IX (II and X) and factor VII
 - 9/02 Improved ion-exchange and affinity chromatography of vitamin K dependent factors
 - 9/03 Improved concentrate of thrombin for clinical and laboratory use

Topic : Fibrinogen

Project Code

Project Code

Estimated Budget : £13,600

- PG/01 Preparation for clinical and laboratory use
- FG/02 Quantitative analysis
- PG/04 Fibrinopeptide analysis
- FG/05 Fibrinolytic potential of factor VIII concentrate

Topic : Pibronectin

Estimated Budget : £23,200

FN/01 A potential clinical product
 FN/02 Reagent grade product
 FN/04 Fibronectin and Factor VIII
 FN/06 Degradation products - isolation, identification and quantitation
 * FN/35 Fibronectin : opsonic activity and functional assay development

Topic : Pactor XIII

Project Code

Estimated Budget : £Nil

13/01 A concentrate for clinical use

Topic : Antithrombin III/Factor XI

Project Code

Estimated Budget : £10,000

AT3/01 Concentrates for clinical use

Estimated Budget : £44,250

jooject Code

- ALB/01 Large scale production of reagent grade material from Cohn Fraction
- ALB/02 Automation of large scale affinity chromatography process
- ALB/05 Recovery from pathological plasmas
- * ALB/34 Albumin : traditional and polymer-enhanced serological reagents

Topic : Immunoglobulin Production

Project Code

Estimated Budget : £124,400

- IgG/01 Development of a preparation for intravenous use
- 19G/02 Clinical trial of intravenous preparation
- Trial of prophylactic immunoglobulin to prevent CMV infections in CMV seronegative bone marrow transplant recipients 1gG/03
- * IgG/08 Anti-D immunoglobulin : acid/pepsin treated for intramuscular preparation
- Immunoglobulins : evaluation of virucidal treatments * 1gG/09

Topic : Ethanol Fractionation

Project Code

Estimated Budget : £1,000

- Filtration of cold-ethanol supernatants using non-asbestos filter EF/02
- Filtration of normal immunoglobulin using non-asbestos filter media * EF/05

Topic : Coagulation Pactors Production

Project Code

Estimated Budget : £175,800

- Computer technology for plasma receipt/guarantine/batching Schubert filling machine : development of a filling pump/needle CF/01
- CF/02 Factor VIII production : commissioning of plasma crusher/thawing
- CF/03 vessel
- Tear-Down Machine : development and evaluation CF/04
- Factor IX production : recycling and centrifugation of DE52
- CF/05 Baemonetics pack-opening machine
- * CF/06 Coagulation factors : provision of ovens for heat treatment * CF/07

Topic : Potential Products

Project Code

Estimated Budget : £56,650

- a-l-Antitrypsin : distribution and purification by selective AT/01 precipitation
- a-1-Antitrypsin : chromatographic fractionation * AT/23
- Lys-plasminogen preparation and production * PMG/01
- plasminogen : preparation of a reagent-grade product PMG/02
- Somatomedin C, purification and assay SMC/01
- TCS/01 Development of tissue culture supplements
- Transferrin : distribution and fractionation Tf/01
- Clq/01 Isolation of complement component : Clq



Topic : Analytical Developments

Estimated Budget : £32,850

Project Code

- HEP/02 Antibody to Hepatitis B surface antigen
 LAL/01 Validation of LAL assay for albumin and other blood proucts
 LAL/02 Chromogenic substrate test : validation for selected blood products
 LAL/03 Coagulation factors : LAL tests and anomalous rabbit pyrogen tests
 IgG/05 ELISA for determination of antiviral IgG
 IgG/06 Antiviral/antitoxin antibody assay development
 IgG/07 Bacterial lipopolysaccharide : antibody screening
 BM/01 Screening test for B-2-microglobulin
 HDLC/01 High pressure liquid chromatography : protein analysis HPLC/01 High pressure liquid chromatography : protein analysis BPLC/02 High pressure liquid chromatography : analysis of low molecular weight compounds

Topic : Process Development

Project Code

Estimated Budget : £84,300

3GA/02 Cibacron blue-Sepharose : ligand leakage 3GA/03 Cibacron blue-Sepharose : toxicity studies production of a magnetic matrix for chromatography * ADC/01 Ampholyte displacement chromatography and chromatofocussing : plasma protein fractionation * CBR/01 Chromatography adsorbents : comparative studies * MAB/01 Monoclonal antibody/cell culture facility

* COM/01 Computer Applications

Topic : Concluded Projects

Project Code

pp/01 Distribution of plasma proteins in 512 protects	8/09 FG/03 FN/03 FN/05 ALB/03 ALB/04 3GA/01 BEP/03 AT/02 AT/03 19G/04 EF/01 EF/03 EF/04	Ethanol fractionation r concentration of albumin solutions using non- Ethanol fractionation : filtration of albumin solutions using non- asbestos filter media Application of Westfalia bowl centrifuges in cold ethano!	
	PP/01	fractionation Distribution of plasma proteins in BPL products and waste fractions	



Topic : Analytical Developments

Estimated Budget : £32,850

Project Code

. .

- CP/02 Antibody to Hepatitis B surface antigen
- LAL/OI Validation of LAL assay for albumin and other blood proucts
- LAL/02 Chromogenic substrate test : validation for selected blood products
- LAL/03 Coagulation factors : LAL tests and anomalous rabbit pyrogen tests
- IgG/05 ELISA for determination of antiviral IgG
- 1gG/06 Antiviral/antitoxin antibody assay development
- * 1gG/07 Bacterial lipopolysaccharide : antibody screening
- Screening test for B-2-microglobulin
- HPLC/01 High pressure liquid chromatography : protein analysis HPLC/02 High pressure liquid chromatography : analysis of low molecular * BM/01 weight compounds

Topic : Process Development

Project Code

Estimated Budget : £84,300

3GA/02 Cibacron blue-Sepharose : ligand leakage

- 3GA/03 Cibacron blue-Sepharose : toxicity studies
- Production of a magnetic matrix for chromatography
- ADC/01 Ampholyte displacement chromatography and chromatofocussing : plasma protein fractionation
- Chromatography adsorbents : comparative studies CHR/01 Chromatography adsorbents : comparative st
 MAB/01 Monoclonal antibody/cell culture facility
 COM/01 Computer Applications

Topic : Concluded Projects

Project Code

8/08 8/09 FG/03	Factor VIII : Chromatography in relation to ligand substitution Factor VIII : Immunoadsorbent chromatography Fibrinogen : qualitative analysis Fibronectin : as a non-immune opsonin
FN/03	
PN/05	Albumin : development and characterisation of serological reagent
ALB/03	
ALB/04	A A A A A A A A A A A A A A A A A A A
3GA/01	Cibacion Dide-Sepherose, ortende
	pyrogens BPL-radioimmunoassay for hepatitis B surface antigen
BEP/01	BPL-radioimmunoassay for hepatitis infectivity Screening tests for markers of hepatitis infectivity
BEP/03	screening tests for markers of hepotagraphic fractionation a-1-Antitrypsin : conventional chromatographic fractionation
AT/02	a-1-Antitrypsin : affinity chromatography adsorbents
AT/03	a-1-Antitrypsin : allinity chronacography BKA6 centrifuge Immunoglobulin : evaluation of Westfalia BKA6 centrifuge
19G/04	Immunoglobulin : evaluation of westing have centration supernatant by Ethanol fractionation : concentration of factor IX supernatant by
EF/01	Ethanol fractionation : concentration of factor in opposite
·	ultrafiltration
EF/03	ultrafiltration Ethanol fractionation : filtration of albumin solutions using non-
	asbestos filter media
EF/04	asbestos filter media Application of Westfalia bowl centrifuges in cold ethano]
w1 / **	
PP/01	fractionation Distribution of plasma proteins in BPL products and waste fractions

. ..



Topic : Analytical Developments

Estimated Budget : £32,850

Project Code

- Antibody to Hepatitis B surface antigen
 LAL/01 Validation of LAL assay for albumin and other blood proucts
 LAL/02 Chromogenic substrate test : validation for selected blood products
 LAL/03 Coagulation factors : LAL tests and anomalous rabbit pyrogen tests
 LAL/03 ELISA for determination of antiviral IgG
 19G/06 Antiviral/antitoxin antibody assay development
 19G/07 Bacterial lipopolysaccharide : antibody screening
 19G/07 Screening test for B-2-microglobulin
- * BM/01 Screening test for B-2-microglobulin BPLC/01 High pressure liquid chromatography : protein analysis EPLC/02 High pressure liquid chromatography : analysis of low molecular weight compounds

Topic : Process Development

Project Code

Estimated Budget : £84,300

3GA/02 Cibacron blue-Sepharose : ligand leakage 3GA/03 Cibacron blue-Sepharose : toxicity studies

- Production of a magnetic matrix for chromatography * ADC/01 Ampholyte displacement chromatography and chromatofocussing : plasma
- protein fractionation * CHR/01 Chromatography adsorbents : comparative studies
- * MAB/01 Monoclonal antibody/cell culture facility
- * COM/01 Computer Applications

Topic : Concluded Projects

Project Code

roject Co	de
8/08	Factor VIII : Chromatography in relation to ligand substitution Factor VIII : Immunoadsorbent chromatography Factor VIII : Immunoadsorbent chromatography
MI W #	
FG/03	Fibrinogen : qualitation opsonin Fibronectin : as a non-immune opsonin
FN/03	Fibronectin : as a non-the development
FN/05	Fibronectin : as a non development Fibronectin : assay kit development
1 11/ 42	ADDRING ADDRIDUNCIL ON STATES
ALB/03	Albumin : development and characteristical reagent Albumin : polymer enhanced serological reagent Albumin : polymer enhanced : affinity of hepatitis B particle and
ALB/04	Albumin : polymer enhanced serological reagent Albumin : polymer enhanced serological reagent Cibacron blue-Sepharose : affinity of hepatitis B particle and
3GX/01	
	pyrogens BPL-radioimmunoassay for hepatitis B surface antigen
BEP/01	BPL-radionauto for markets of hepatitis infectivity
BEP/03	screening tests is a seconstraphic fractionation
AT/02	a 1 Antitivosin i Concerciona and adeorbents
AT/03	a a make is warred in 2 with the 2 """""""""""""""""""""""""""""""""""
19G/04	
199/ 03	
EF/01	ultrafiltration Ethanol fractionation : filtration of albumin solutions using non Ethanol fractionation
	reparal fractionation : filtration of albumin but
EF/03	asbestos filter media Application of Westfalia bowl centrifuges in cold ethano
	aspestos trion of Westfalia bowl centriluges in core contra
EF/04	Application of motions
	fractionation
PP/01	Application of an area from the second secon

. .



Topic : Albumin Estimated Budget : £44,250 : Project Code ALB/01 Large scale production of reagent grade material from Cohn Fraction ALB/02 Automation of large scale affinity chromatography process ALB/05 Recovery from pathological plasmas * ALB/34 Albumin : traditional and polymer-enhanced serological reagents Topic : Immunoglobulin Production Estimated Budget : £124,400 Project Code \ IgG/01 Development of a preparation for intravenous use 1 19G/02 Clinical trial of intravenous preparation 1gG/03 Trial of prophylactic immunoglobulin to prevent CMV infections in CMV seronegative bone marrow transplant recipients * IgG/08 Anti-D immunoglobulin : acid/pepsin treated for intramuscular preparation * IgG/09 Immunoglobulins : evaluation of virucidal treatments Topic : Ethanol Fractionation Estimated Budget : £1,000 project Code Filtration of cold-ethanol supernatants using non-asbestos filter EF/02 Filtration of normal immunoglobulin using non-asbestos filter media • EF/05 Topic : Cosquiation Factors Production Estimated Budget : £175,800 Project Code Computer technology for plasma receipt/quarantine/batching Schubert filling machine : development of a filling pump/needle CF/01 ĊF/02 Factor VIII production : commissioning of plasma crusher/thawing CF/03 vessel Tear-Down Machine : development and evaluation Factor IX production : recycling and centrifugation of DE52 CF/04 CF/05 Haemonetics pack-opening machine Coagulation factors : provision of ovens for heat treatment * CF/06 * CF/07 Topic : Potential Products Estimated Budget : £56,650 Project Code a-l-Antitrypsin : distribution and purification by selective AT/01 precipitation a-1-Antitrypsin : chromatographic fractionation * AT/23 * PMG/01 Lys-plasminogen preparation and production * PMG/02 Plasminogen : preparation of a reagent-grade product SMC/01 Somatomedin C, purification and assay TCS/01 Development of tissue culture supplements Transferrin : distribution and fractionation Tf/01

Clg/01 Isolation of complement component : Clg

DATESTIN

p hand f



BLOOD PRODUCTS LABORATORY

National Blood Transfusion Service

Director: R. S. LANE, MD MRCP MRCPath. Telephone: 01-953-6191 Telex: 8814267

Dagger Lane, Elstree,	(4075
Boreham	wood,
Herts	WD6 3BX.

Our Ref:

25th July 1985

To: Regional Transfusion Directors ; England and Wales

Dear Dr

DRIED FACTOR VIII FRACTION : TYPE 8Y

It was announced at the last RTD meeting that Factor 8Y would commence issue in September 1985 at a level of 7500 vials (250 iu) per month. This level of output will not increase until the new production unit is operational. Note that for September only, the issue will be part HLH and part 8Y.

Accordingly a letter has been sent to all Haemophilia Directors and a copy is attached for your information. You will see that it is hoped that active liason between Haemophilia Centres and RTCs will result in a high proportion of Factor 8Y being given to patients most at risk to infection by HTLV III and viruses associated with Non A Non B hepatitis.

A percentage of Factor 8Y is being used in clinical trials in selected patients to determine safety and efficacy of product prior to making application for a product licence in the autumn.

If you have any comments, please do not hesitate to contact me.

Yours sincerely

HAEMOPHILIA CENTRES ANNUAL RETURNS 1984

4

1

As you suggest I will speak to ! · about the possibility of obtaining earlier returns for Departmental purposes. Are you prepared to fund the extra effort which would be required to produce these figures?

the please

` (ii

I think it probably would be useful to ask the Haemophilia Reference Centre Directors how they see the latest projection of UK needs for Factor VIII. I will make enquiries about how the projected figure was proposed to make the original calculations before approaching them.

5 November 1985

Room 1025a Han Hse Ext 3487

cc

r,